Ikuo Kashiwakura

Prof. Ikuo Kashiwakura

Hirosaki Univercity
orcid

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 July 2018 in Scientific Reports
Verified
Journal Article
Open access
PDF file
MYMasaru Yamaguchi
Masaru Yamaguchi
THTokuhisa Hirouchi
Tokuhisa Hirouchi
KYKoki Yokoyama
Koki Yokoyama
ANAyaka Nishiyama
Ayaka Nishiyama
SMSho Murakami
Sho Murakami
IKIkuo Kashiwakura
Ikuo Kashiwakura
For the primary treatment of emergency exposure to high-dose radiation, such as in the event of a radiation accident, the top priority is the reconstitution and restoration of haematopoiesis. In most radiation accidents, drug therapy is chosen as the most suitable treatment; the chosen drug should already be approved domestically, stably supplied and regularly stockpiled. In the present study, a single administration of romiplostim (RP), an approved thrombopoietin receptor agonist, produced a 100% survival rate in C57BL/6 J mice exposed to a lethal dose (7 Gy) of137Cs γ-rays, and all irradiated mice survived for more than 30 days with both 3- and 5-day consecutive administrations. By day 30, the peripheral blood cells, bone marrow cells and haematopoietic progenitor cells of the RP-administered irradiated mice had all recovered to a level that was not significantly different from that in non-irradiated mice. In contrast to myelosuppression, which did not fully recover until day 30, the expression of several bone marrow cell surface antigens recovered sooner, and DNA repair concurrently increased in haematopoietic cells, speeding the resolution of double strand breaks and reducing the rates of apoptosis. These findings suggest that RP may be a clinic-ready countermeasure to treat victims of radiation accidents.

13 June 2008 in Investigational New Drugs
Verified
Journal Article
Closed access
PDF file
MHMasaharu Hazawa
Masaharu Hazawa
KWKoji Wada
Koji Wada
KTKenji Takahashi
Kenji Takahashi
TMTakao Mori
Takao Mori
NKNorio Kawahara
Norio Kawahara
IKIkuo Kashiwakura
Ikuo Kashiwakura

1 August 2010 in Radiation Research
Verified
Journal Article
Closed access
KKKengo Kato
Kengo Kato
KTKenji Takahashi
Kenji Takahashi
SMSatoru Monzen
Satoru Monzen
HYHiroyuki Yamamoto
Hiroyuki Yamamoto
AMAtsushi Maruyama
Atsushi Maruyama
IKIkuo Kashiwakura
Ikuo Kashiwakura
NFE2-related factor 2 (Nrf2), which belongs to the cap “n” collar family of basic region leucine zipper transcription factors, is a key protein in the coordinated transcriptional induction of expression of various antioxidant genes. The purpose of this study was to analyze the expression of Nrf2 target genes, such as heme oxygenase 1 (HO-1), ferritin heavy polypeptide 1 (FTH1), NAD(P)H dehydrogenase, quinone 1 (NQO1), glutamate-cysteine ligase catalytic subunit, glutamate-cysteine ligase modifier subunit, glutathione reductase (GSR) and thioredoxin reductase 1 (TXNRD1), after X irradiation of CD34+ cells that were prepared from human placental/umbilical cord blood hematopoietic stem cells (HSCs). We evaluated the relationship between radiosensitivity and expression of Nrf2 target genes in HSCs. The number of colony-forming cells derived from 2-Gy-irradiated HSCs decreased to approximately 20% of the nonirradiated control. At the same time, the mRNA expression of HO-1, FTH1, NQO1, GSR and TXNRD1 w...

26 September 2009 in Investigational New Drugs
Verified
Journal Article
Closed access
PDF file
MHMasaharu Hazawa
Masaharu Hazawa
KTKenji Takahashi
Kenji Takahashi
KWKoji Wada
Koji Wada
TMTakao Mori
Takao Mori
NKNorio Kawahara
Norio Kawahara
IKIkuo Kashiwakura
Ikuo Kashiwakura

25 July 2013 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MYMasaru Yamaguchi
Masaru Yamaguchi
IKIkuo Kashiwakura
Ikuo Kashiwakura
Hematopoietic stem/progenitor cells (HSPCs), which are present in small numbers in hematopoietic tissues, can differentiate into all hematopoietic lineages and self-renew to maintain their undifferentiated phenotype. HSPCs are extremely sensitive to oxidative stressors such as anti-cancer agents, radiation, and the extensive accumulation of reactive oxygen species (ROS). The quiescence and stemness of HSPCs are maintained by the regulation of mitochondrial biogenesis, ROS, and energy homeostasis in a special microenvironment called the stem cell niche. The present study evaluated the relationship between the production of intracellular ROS and mitochondrial function during the proliferation and differentiation of X-irradiated CD34+ cells prepared from human placental/umbilical cord blood HSPCs. Highly purified CD34+ HSPCs exposed to X-rays were cultured in liquid and semi-solid medium supplemented with hematopoietic cytokines. X-irradiated CD34+ HSPCs treated with hematopoietic cytokines, which promote their proliferation and differentiation, exhibited dramatically suppressed cell growth and clonogenic potential. The amount of intracellular ROS in X-irradiated CD34+ HSPCs was significantly higher than that in non-irradiated cells during the culture period. However, neither the intracellular mitochondrial content nor the mitochondrial superoxide production was elevated in X-irradiated CD34+ HSPCs compared with non-irradiated cells. Radiation-induced gamma-H2AX expression was observed immediately following exposure to 4 Gy of X-rays and gradually decreased during the culture period. This study reveals that X-irradiation can increase persistent intracellular ROS in human CD34+ HSPCs, which may not result from mitochondrial ROS due to mitochondrial dysfunction, and indicates that substantial DNA double-strand breakage can critically reduce the stem cell function.

11 November 2015 in Current Pharmaceutical Biotechnology
Verified
Journal Article
Closed access
PDF file
THTokuhisa Hirouchi
Tokuhisa Hirouchi
KIKoichi Ito
Koichi Ito
MNManabu Nakano
Manabu Nakano
SMSatoru Monzen
Satoru Monzen
HYHironori Yoshino
Hironori Yoshino
IKIkuo Kashiwakura
Ikuo Kashiwakura
It is important to establish an easy-to-use therapeutic protocol for the emergency medical care of patients involved in radiation accidents to reduce the radiation-related casualties. The present study aimed to establish an optimum therapeutic protocol using currently approved pharmaceutical drugs to increase the survival of victims exposed to lethal radiation. Different combinations of four drugs-recombinant human erythropoietin (EPO), granulocyte-colony stimulating factor (G-CSF), c-mpl receptor agonist romiplostim (RP) and nandrolone decanoate (ND)-were administered to mice within 2 h after exposure to a lethal 7 Gy dose of γ-irradiation. On day 30 after irradiation, the condition of the mice was analyzed using various hematological parameters, such as the number of peripheral blood cells, bone marrow cells, hematopoietic progenitor cells and the expression of cell surface antigens. Approximately 10% of the untreated irradiated control mice survived for 21 days, but all of the control mice died by day 30. The combined administration of G-CSF, EPO and RP for five days immediately after irradiation led to a complete survival of the irradiated mice until day 30. However, the treatment with G-CSF, EPO and RP with ND led to only 75% survival at day 30. The hematological analyses showed that the numbers of almost all of hematopoietic cells in the surviving mice treated with effective medications recovered to the levels of non-irradiated mice. The present findings show that the combination of G-CSF, EPO and RP may be a useful countermeasure for victims exposed to accidental lethal irradiation.